WuXi Discovery Services’ Post

Only 1% of an ADC dose reaches the tumor, with 99% eliminated by normal tissues, contributing to toxicity that limits efficacy. How do we solve this to maximize the therapeutic index of powerful cancer drugs?    Separation of tumor targeting from payload!     We infuse an antigen binder activator that does not carry payload, then we infuse an inert protodrug, which finds the activator at the tumor and, Click! A click chemistry reaction occurs on the surface of the cell, releasing the active payload at the tumor. In addition to limiting exposure to normal tissues, the separation of components also allows us to find the optimal activator to protodrug ratio.     Find out more in this clip from our animation and click below to watch the full video.     www.shasqi.com/our-science    #oncology #innovation #ADCs  

Test your EGFR and MET targeted therapeutics ex vivo and in vivo and further your NSCLC drug pipeline with Champions' unique PDX model, CTG-3414. CTG-3414 is an EGFR+ MET+ NSCLC PDX model derived from a patient pre-treated with osimertinib. Full clinical annotations and deep characterization with NGS, proteomics, and response to standards of care are available for this model. Contact us to learn more about this unique model https://hubs.li/Q02nhQ5-0 #NSCLC #modelspotlight #lungcancer #lung #oncologyresearch #oncology #cancerresearch #cancer #tumor #EGFR #MET #PDX #osimertinib #targetedtherapy

🐁 Discover how to build the optimal preclinical model for cancer drug discovery in just 30 minutes! We’ll explore CDX vs. PDX, tumor microenvironment, study design, and published data: https://bit.ly/3PVjJAN

NSD2: IS THIS THE PROTEIN THAT TRIGGER PROSTATE CANCER? Why does a typically normal protein goes out of control and fuel cancer? A possible answer comes from scientists at the University of Michigan Health Rogel Cancer Center. They found the protein NSD2 alters the function of the androgen receptor, an important regulator of normal prostate development. When the androgen receptor binds with NSD2, it causes rapid cell division and growth leading to prostate cancer. The study published on September 9, in Nature Genetics [DOI: 10.1038/s41588-024-01893-6], may suggest a new way to therapeutically target prostate cancer. #cancer #NSD2 #prostatecancer

🌟 Did you know? The Clonogenic Assay, developed by Dr. Puck and Dr. Marcus in 1956, remains a cornerstone in cancer research and drug discovery. 🌟 This assay, originally designed to measure the survival of cells after radiation, has since become a powerful tool for assessing the efficacy of anti-cancer drugs. By evaluating a drug’s ability to prevent cancer cells from forming colonies, researchers can gain critical insights into potential treatments. 🧬 In the rapidly evolving field of oncology, techniques like the clonogenic assay play a pivotal role in moving science forward. Whether it’s testing novel compounds or refining treatment strategies, this assay is a reminder of how foundational research can lead to life-saving innovations💡 #CancerResearch #DrugDiscovery #ClonogenicAssay #Oncology #MolecularBiology #InnovationInScience #ResearchMatters

🔬 Join Wren Laboratories for an upcoming webinar to explore the transformative potential of #liquidbiopsy and multigene mRNA expression assays in clinical trials. Abdel Halim, PharmD, MSc, PhD, DABCC will showcase the clinical validity of NETest® and PROSTest® assays for neuroendocrine tumors and prostate cancer, while also discussing their use in biomarker discovery, proof-of-concept (POC), and pharmacodynamics (PD) studies. 🔍 Learn more + register here: https://buff.ly/3XiuxvK #Biopsy #PrecisionMedicine #ClinicalResearch #Oncology #Biomarkers #CDx #Diagnostics #TherapeuticAreas #LaboratoryTechnology #LiquidBiopsyCancer

We are pleased to announce the publication of new preclinical data from a study of BTX-A51 in human liposarcoma (LPS), conducted by Dana-Farber Cancer Institute and Hebrew University-Hadassah Medical School, and presented at the American Association of Cancer Research Annual Meeting 2024. The data demonstrate that BTX-A51 has preclinical efficacy in treating patient-derived LPS in cell lines and human xenograft models and provides insight into the synergy gained by inhibiting both CK1alpha and CDK9. Read the press release and learn more about Edgewood Oncology at www.edgewoodoncology.com #biotech #oncology #liposarcoma #precisionmedicine

  https://lnkd.in/dJ65SMZB Researchers at Ben-Gurion University of the Negev have developed a nano-sized polymer that can deliver chemotherapy drugs directly to the blood vessels that feed cancer cells both in tumors and metastases (breakaways from a main tumor). The polymer has shown to be an effective treatment for advanced cancer, the university said, in trials eliminating colorectal cancer cells that had metastasized in the liver after a single dose. “Our unique polymer demonstrates promising preclinical results for treating advanced cancer that has spread to other places in the body and usually cannot be cured or controlled with other therapies,” said Prof. Ayelet David. #polymer #chemotherapy #bloodvessels #medicalresearch #israelinnovation #cancertreatments #cancercells https://lnkd.in/dJ65SMZB

I want to share our latest paper titled "Targeted Nano-Delivery of Flutamide with polymeric and lipid nanoparticles" published in the European Polymer Journal. Our comprehensive review delves into the progress and modifications in intelligent delivery methods for Flutamide (FLT), a critical drug for treating androgen-dependent malignancies like prostate cancer and conditions like polycystic ovarian syndrome. The paper opens new possibilities for advanced cancer therapies, emphasizing the transformative potential of NDDS with polymeric nanoparticles. A huge thanks to #Amirhossein_Khanizadeh for his invaluable assistance in this project. #CancerResearch #Nanotechnology #DrugDelivery #PolymericNanoparticles #Flutamide #ProstateCancer #ScientificResearch

Researchers are investigating nanoparticle-based drug delivery for enhanced ovarian cancer treatment. Overcoming challenges associated with traditional chemotherapy, nanoparticles offer precise drug delivery, minimizing side effects. Various nanoparticle types, including organic and inorganic variants, demonstrate improved stability and specific tumor targeting. Active mechanisms, such as aptamer binding, contribute to enhanced targeting precision. Despite ongoing research, nanoparticle-based drug delivery holds promise as an innovative and efficient approach for ovarian cancer treatment with minimal side effects. Read more: https://lnkd.in/dQJAFmci #aptamer #research #oncology #medical #biology